K. L. Gully

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination

This study shows that non-neutralizing antibodies targeting FcR4 and spike S2 provide cross-protection against sarbecoviruses after alphavirus vector vaccination.

A Multitrait Locus Regulates Sarbecovirus Pathogenesis

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies

This paper develops a murine model of persistent post-SARS-CoV-2 lung disease to identify therapeutic targets and test interventions for PASC.

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

This paper develops a mouse-adapted SARS-CoV-2 model to evaluate medical countermeasures, showing age-related disease severity and the efficacy of IFN lambda-1a.

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.